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Accepted 17 June 2010The prevalence of endometriosis may be up to 22% of
asymptomatic women and 30% of women with infertility [1].
It is also estimated that 17e44% of all patients undergoing in
vitro fertilization (IVF) have ovarian endometrioma [2,3]. The
optimal treatment for endometrioma is still a controversial
issue. Traditionally, the management approach toward endo-
metrioma has been either surgical or hormonal. But, neither
has a clear-cut advantage over the other in terms of repro-
ductive success. However, whenever a patient is diagnosed as
having ovarian endometrioma then surgery is advocated, as
these persist despite hormonal treatment [4].
But, in the presence of pelvic adhesion or advanced stages
of endometriosis, it can be difficult to identify anatomic
structures, leading to suboptimal resectioning, frequent cyst
recurrence, and surgical complications. Ultrasonic needle-
guided aspiration of ovarian endometriomas was proposed in
1991 as an alternative for patients who had recurrent
endometriomas or when surgery was contraindicated for
medical or personal reasons [5]. In addition, the interest in
cost-effective outpatient therapy and the expected difficulty
in surgical treatment of recurrent endometriosis made the
aspiration of endometrioma an option before ovulation
induction. Though Pabbuccu et al. [6] reported that aspiration
of endometriomas before controlled ovarian hyperstimulation
(COH) neither reduced the amount of gonadotropins used nor
increased the number of follicles and oocytes retrieved;
Hsieh et al. [7] showed that following aspiration the number
of antral follicles increased. It was also reported by Dicker
et al. [8] that the pregnancy rate improved significantly after
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has been reported that ovarian cystectomy reduced follicle and
oocyte numbers in COH, and patients with compromised
ovarian status had a reduced potential of oocyte recruitment [9].
Many strategies are available for the treatment of poor
responders with varying degrees of success ranging from the
unstimulated cycle to COH with clomiphene citrate, urinary
and recombinant gonadotropins, and adjunctive gonadotropin-
releasing hormone agonists (GnRHa) and antagonists (GnRH-
ant) [10].
Here, we present a case of infertility with bilateral
obstructive fallopian tubes and recurrent endometriomas.
Before enrolling the patient for IVF, she was treated by
repeated aspiration of recurrent endometriomas, then a cumu-
lative strategy of COH regimen was applied for the IVF
program.
A 32-year-old nulliparous woman presented with severe
dysmenorrhea and infertility for 5 years. She gave a history of
a previous conservative surgery 6 years ago for extensive
pelvic endometriosis with a right ovarian endometrioma
measuring about 9 cm  9 cm in diameter. Transvaginal
ultrasonography revealed the presence of bilateral adnexal
cysts, 11 cm  9 cm and 8 cm  6 cm in diameter, with
speckled homogenous echogenicity. Computed tomography
examination revealed bilateral adnexal masses. After coun-
seling, transvaginal ultrasonic needle-guided aspiration of
120 mL of chocolate-like material from the right ovarian cyst
and 80 mL from the left ovarian cyst was performed.
Aspiration was done on a day care basis. The patient was
given slow intravenous preoperative sedation, 50 mg of
pethizine, and 10 mg of pentazocine just before starting the
procedure. An ultrasound examination was carried out just
before aspiration, and the optimal size for puncture was
selected. Transvaginal ultrasonic needle-guided aspiration
of the endometriotic cyst was done using a transvaginal
transducer (5.5 MHz; Aloka, Tokyo, Japan), double lumenscs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Cook, Brisbane, Australia), and suction unit (K-MAR-5100;
Cook, Brisbane, Queensland, Australia).
The progress of the needle was observed through the tissue
on the ultrasound until the tip was visualized well within the
cyst. The needle tip was monitored throughout the whole
procedure. As the endometritic cystic content was so thick,
normal saline irrigation was carried out to complete aspiration.
The aspirate was sent for cytological examination. After
complete evacuation of the cyst, 95% ethanol was irrigated
through the cystic cavity for 10 minutes. Thereafter, the
patient was treated with oral contraceptive pills (OCP) to
control the endometriosis.
Three months later, vaginal ultrasound follow-up revealed
a recurrence of endometriotic cysts which had reached a size
of 8 cm  6 cm and 6 cm  6 cm in diameter. The patient was
counseled again for reaspiration, then COH for IVF was
started in the same cycle after the procedure.
The COH for IVF was the low-dose ultrashort GnRHa,
clomiphene citrate, and gonadotropins with multidose of
GnRH-ant protocol, and entailed the administration of 0.1 mg
buserelin acetate (Supremon; Hoechst AG, Frankfurt an Main,
Germany) subcutaneously for 3 days, starting on Day 2 of the
menstrual cycle and clomiphene citrate, 150 mg (Clomid;
Serono Laboratories, Rome, Italy), starting on the same day
(Day 2) for 5 days. Recombinant follicular stimulating
hormone 150 IU (Gonal-F; Serono Laboratories, Rome, Italy)
and human menopausal gonadotropin 150 IU (HMG, Meno-
pur; Ferring Pharmaceuticals, GmbH, Germany) were started
on Day 3 of the menstrual cycle and continued according to
the ovarian ultrasonic response. After the leading follicle had
reached a size of 14 mm, co-treatment was initiated with the
GnRH-ant (Orgalutron; Organon Ltd., Swords, Co. Dublin,
Ireland) at 0.25 mg per day, which was continued up to and
including the day the recombinant human chorionic gonado-
tropin (rhCG, Ovidrel; Serono Laboratories, SA, Aubonne,
Switzerland) was injected. Folliculometry was performed by
using transvaginal sonography (Aloka, Tokyo, Japan) equip-
ped with a 5-MHz vaginal annual array transducer. When two
or more follicles had reached a diameter of 18 mm, 10,000 IU
of rhCG was given. Follicular aspiration was performed
transvaginally under ultrasonar guidance 36 hours after rhCG
administration, and oocytes were fertilized through conven-
tional IVF. Two oocytes were aspirated and two embryos were
transferred into the uterine cavity transvaginally 72 hours after
ovum pick-up. Micronized progesterone 600 mg/d (Utroge-
stan, Laboratories Piette International SA, Brussels, Belgium)
was administrated after ovum pick-up and rhCG 1500 IU
subcutaneous injection was given every 3 days for a total of
three doses after the embryos were transferred.
The progestin luteal support was continued up to 12 weeks
of gestation. The patient is now going through singleton
gestation.
Ovarian endometriotic cysts might decrease the success of
COH and IVF because of the mechanical effect in which the
ovarian cyst physically reduces the space for more follicles to
develop.The mechanical effect of the mass on the ovarian blood
supply may result in poor ovarian response. In addition, the
ectopic endometrial tissues impair the normal intraovarian
mechanism of follicle and oocyte maturation, which in turn
may affect the quality of the oocyte retrieved [11]. During
ovulation induction, the presence of these cysts could make
the ultrasound monitoring of follicular growth difficult, the
retrieval of ovum more difficult, and in some cases the ovary
inaccessible [5,12e14].
Furthermore, women with severe endometriosis may
perform poorly in an IVF treatment program [14]. Somigliana
et al. [15] reported that the presence of ovarian endometrioma
is associated with a reduced responsiveness to gonadotropins.
This deleterious effect was more evident in women with larger
cysts and in those with more than one cyst. Suzuki et al. [16]
also showed the numbers of retrieved oocytes were fewer in
patients with ovarian endometrioma than in those with a tubal
factor without endometriosis.
Laparotomy is still the conventional treatment of endo-
metriosis and involves the drainage and removal of the cystic
wall. There is evidence that excisional surgery of endome-
trioma provides for a more favorable outcome than drainage
and ablation with regard to recurrence of the endometrioma,
recurrence of pain symptoms, and in women who were
previously subfertile, subsequent spontaneous pregnancy [17].
But, in some patients, operative laparotomy or laparoscopy
may be contraindicated because of previous surgery and/or
adhesion [5,18]. Recurrent endometriomas after laparoscopic
or conservative open surgery for endometriosis is a more
difficult clinical problem for those patients who wish to retain
their fertility potential. The surgery often results in inadver-
tent removal of normal ovarian tissue, which may decrease
the number of oocytes available for subsequent fertility
treatment [19].
It has been reported that previous ovarian surgery might
damage ovarian reserve, resulting in poor ovarian response and
increased cancellation rate during COH for IVF [20]. It also
has been shown that ovarian surgery of cystectomy has an
adverse effect on ovarian response to stimulation with
gonadotropins and thus on the results of fertility treatment
[21]. Hachisuga and Kawarabayashi [22] reported that removal
of the capsule of endometrioma was associated with loss of
follicles and damage to the ovarian stroma. Nargund et al. [23]
suggested that ovarian cystectomy reduced follicle and oocyte
numbers in ovulation induction cycles, and the removal of
endometrioma caused more damage to the ovaries than the
removal of a simple cyst. In addition, a second operation is
seldom effective in preventing recurrence of endometriosis
following an unsuccessful or incomplete first operation [24].
As the management of endometrioma in infertile women
before IVF remains controversial, the management of women
with endometrioma before IVF should be individualized [18].
In spite of the aspiration of ovarian endometrioma having the
disadvantage of a high recurrent rate [25], if fertility is the
aim, aspiration might be a reasonable alternative to ovarian
surgery to decrease the risk of cancellation during COH
because of poor response in IVF protocol.
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of pelvic cysts before COH may improve the outcome of IVF
[12], and a significantly higher number of oocytes were
recovered following aspiration in COH of IVF program [21].
Chang et al. [26] suggested that patients who underwent
aspiration and sclerotherapy for recurrent endometriomas,
resulted in the reduction of cystic size and preservation
of more ovarian tissue made a significant improvement in
folliculogenesis. Chang et al. [7] also found that the number
of antral follicles increased in patients with aspiration and
sclerotherapy with 95% ethanol for treatment of recurrent
ovarian endometriomas. Sclerotherapy may help to preserve
primordial follicles in a population already at risk of decreased
ovarian reserve [18]. Thus for this recurrent endometrioma
patient who wished to have COH for IVF performed, we used
transvaginal ultrasonic needle-guided aspiration of the endo-
metriotic cysts as an optimal line of treatment.
The treatment of low responders with IVF remains a chal-
lenge, and it is extremely important to identify these patients
before initiation of COH for IVF. Many strategies are available
for the treatment of poor responders, including increasing
the dose of used gonadotropins, using GnRH-ant, reducing or
discontinuing the dose of GnRHa, initiating GnRHa and
gonadotropins together in the follicular phase (the so-called
ultrashort or short flare protocols), and using a microdose
GnRHa flare protocol [9,10,27].
Nevertheless, no compelling advantage has been estab-
lished for one stimulation protocol over another [28]. Bergen
et al. [29] reported that combining the microdose flare GnRHa
and GnRH-ant protocols in poor responders who previously
had failed several IVF treatment cycles resulted in an
acceptable clinical pregnancy rate. Orvieto et al. [28] reported
a COH protocol, which included ultrashort GnRHa combined
with GnRH-ant resulted in a higher number of oocytes and
top-quality embryos than the patient’s previously failed IVF
attempt. D’Amato et al. [30] proposed a protocol of COH with
GnRH-ant, high dose recombinant follicular stimulating
hormone, and clomiphene citrate for poor responders and
obtained lower cancellation rates and higher oocyte retrieval,
implantation rates, and pregnancy rates.
In the present case, we used a cumulative strategy
protocol of COH for the potentially low-responder patient to
increase endogenous gonadotropin and estradiol secretion,
and avoid premature luteinizing hormone (LH) surges. We
combined the beneficial effects of OCP pretreatment, the
clomiphene citrate, and the low-dose ultrashort GnRHa with
that of the GnRH-ant. First, pretreatment with OCP was
shown to synchronize follicular development and eliminate
the existing corpus luteum and restore sensitivity in the
ovarian follicles to exogenous FSH [31,32]. Second, clomi-
phene citrate administration in the early follicular phase,
which stimulate gonadotropins release at the pituitary level
(flare effect) and estradiol secretion from granulosa cells
[33]. Third, following the clomiphene citrate and HMG
treatment there was a lower rate of fracture zona oocytes,
higher rates of fertilization, and normal growth of fertilized
eggs [34].The low-dose ultrashort GnRHa protocol provokes secre-
tion of gonadotropins in the early follicular phase [35]. But,
Hazout et al. [36] observed that the 3-day ultrashort GnRHa/
HMG protocol did not reliably prevent premature LH surges
and so some premature LH surges may occur. The addition of
GnRH-ant to ovarian stimulation during the late follicular
phase will prevent premature LH surges while not causing any
suppression in the early follicular phase, which is a critical
period of patients with decreased ovarian reserves [37].
Moreover, GnRH-ant provides immediate LH suppression
with the possible improvement of the generated embryo [29].
In conclusion, for the purpose of reducing the sequels of
operative laparoscopy or laparotomy of ovarian endome-
trioma, transvaginal ultrasonic needle-guided aspiration was
used as an alternative for the management of recurrent
endometrioma. The procedure is simple, safe, and repeatable
in the treatment of selected cases of endometrioma. We also
proposed a cumulative strategy COH protocol entailing the use
of clomiphene citrate, gonadotropins, low-dose ultrashort
GnRHa, and multiple doses of GnRH-ant to the potentially
poor responder.References
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